Barely Significant
← all excerpts

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.

Indian J Endocrinol Metab · 2019 · PMC6540886 · PMID 31161099

Europe PMCDOI
2
hedged sentences
0.1700
closest p · 3.4× alpha
0.1700
boldest claim

The sentences

a nonsignificant trendP = 0.17not close (p > 0.1)
FIGHT (Functional impact of GLP-1 for heart failure treatment in patient with advanced heart failure) study ( N = 300) conducted with liraglutide (Median left ventricular ejection fraction of 25%) had a nonsignificant trend of increase in HHF (HR = 1.30, 95% CI 0.89-1.88, P = 0.17) and death (HR = 1.10, 95% CI, 0.57-2.14, P = 0.78).[ 28 ] Another study LIVE (Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus) also found a significant increase in serious adverse cardiac events with liraglutide (12 vs. 3, P = 0.04), compared to placebo.[ 29 ] Forest plot in Figure 6 summarizes the HHF outcomes in all CVOTs.

also in 5,406 other papers

nominally significantno p-value reported
Furthermore, semaglutide has shown a significant reduction in non-fatal stroke, while albiglutide has shown a nominally significant reduction in MI.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.